Exhibit 21 — Maine Board of Pharmacy Statement — Apter v. HHS

Summary

Exhibit 21, Document 1-21, filed 06/02/22, in the U.S. District Court for the Southern District of Texas, Galveston Division, in Apter v. Department of Health and Human Services, No. 3:22-cv-00184. It is Board Statement #01-2021 of the Maine Board of Pharmacy, issued September 28, 2021, on dispensing ivermectin. The statement says there have been reports nationally and in Maine of an increase in ivermectin prescriptions to prevent or treat COVID-19, and reminds Maine pharmacists that the U.S. FDA states ivermectin is not authorized or approved for that use. It cites a U.S. CDC Health Alert of August 26, 2021 on increased dispensing and adverse effects, and says pharmacists should use professional and clinical judgment and verify with the prescriber that new ivermectin prescriptions are issued for legitimate medical purposes.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Record facts

Full text

Exhibit 21
Case 3:22-cv-00184   Document 1-21   Filed on 06/02/22 in TXSD   Page 1 of 2

MAINE DEPARTMENT OF PROFESSIONAL & FINANCIAL REGULATION 
Office of Professional and Occupational Regulation 
BOARD OF PHARMACY 
35 State House Station, Augusta, ME 04333 
Location: Gardiner Annex, 76 Northern Avenue, Gardiner, ME 04345 
Web Address:   www.maine.gov/professionallicensing
Janet T. Mills 
 Governor 
BOARD STATEMENT  #01-2021 
MAINE BOARD OF PHARMACY 
(9/28/2021)
STATEMENT OF THE MAINE BOARD OF PHARMACY 
ON DISPENSING IVERMECTIN 
There have been reports nationally, as well as in Maine, of an increase in the number of 
ivermectin prescriptions issued by health care practitioners to prevent or treat COVID-19.  
IN ORDER TO PROTECT THE PUBLIC HEALTH AND WELFARE, THE BOARD 
REMINDS MAINE PHARMACISTS THAT: 
The United States Food and Drug Administration (U.S. FDA) states that ivermectin is not 
authorized or approved for use in prevention or treatment of COVID-19. According to U.S. 
FDA, ivermectin is approved for human use to treat infections caused by some parasitic 
worms, head lice and skin conditions like rosacea. More information from U.S. FDA is found 
here: U.S. FDA Consumer Update on Ivermectin for Human Use. 
The United States Centers for Disease Control and Prevention (U.S. CDC) issued a Health 
Alert on August 26, 2021, concerning the increased dispensing of ivermectin by retail 
pharmacies. The Health Alert states that adverse effects associated with ivermectin misuse 
and overdoses are increasing, as shown by a rise in calls to poison control centers reporting 
overdoses and more people experiencing adverse effects. More information from U.S. CDC 
is found here: U.S. CDC Health Advisory, August 26, 2021.  
Pharmacists should use their professional and clinical judgment and take appropriate steps to 
verify with the applicable prescriber that newly issued prescriptions for ivermectin are issued 
for legitimate medical purposes. 
Issued: September 28, 2021 
-
End    -
Case 3:22-cv-00184   Document 1-21   Filed on 06/02/22 in TXSD   Page 2 of 2

File and source

File

gov.uscourts.txsd.1875135.1.21.pdf

Size

169,033 bytes

SHA-256

17ae09bae6ea720edcf053cc873587364002560b56a1d780472f72072914ad5c

Our copy

gov.uscourts.txsd.1875135.1.21.pdf

Original

archive.org